- Home
- PTGX vs TMDX Comparison
PTGX vs TMDX Comparison
Compare PTGX & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- TMDX
- Stock Information
- Founded
- PTGX 2006
- TMDX 1998
- Country
- PTGX United States
- TMDX United States
- Employees
- PTGX N/A
- TMDX N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PTGX Health Care
- TMDX Health Care
- Exchange
- PTGX Nasdaq
- TMDX Nasdaq
- Market Cap
- PTGX 2.9B
- TMDX 2.3B
- IPO Year
- PTGX 2016
- TMDX 2019
- Fundamental
- Price
- PTGX $47.47
- TMDX $127.12
- Analyst Decision
- PTGX Strong Buy
- TMDX Buy
- Analyst Count
- PTGX 8
- TMDX 10
- Target Price
- PTGX $66.50
- TMDX $122.89
- AVG Volume (30 Days)
- PTGX 789.1K
- TMDX 1.2M
- Earning Date
- PTGX 05-06-2025
- TMDX 05-08-2025
- Dividend Yield
- PTGX N/A
- TMDX N/A
- EPS Growth
- PTGX N/A
- TMDX N/A
- EPS
- PTGX 0.86
- TMDX 1.41
- Revenue
- PTGX $207,801,000.00
- TMDX $488,227,000.00
- Revenue This Year
- PTGX N/A
- TMDX $32.58
- Revenue Next Year
- PTGX $50.30
- TMDX $21.65
- P/E Ratio
- PTGX $55.04
- TMDX $90.23
- Revenue Growth
- PTGX N/A
- TMDX 64.43
- 52 Week Low
- PTGX $27.00
- TMDX $55.00
- 52 Week High
- PTGX $60.60
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- PTGX 58.60
- TMDX 76.52
- Support Level
- PTGX $45.43
- TMDX $118.79
- Resistance Level
- PTGX $46.80
- TMDX $130.48
- Average True Range (ATR)
- PTGX 1.54
- TMDX 4.49
- MACD
- PTGX 0.34
- TMDX -0.15
- Stochastic Oscillator
- PTGX 94.26
- TMDX 83.53
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.